MedTrace Logo

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

NCT03266965 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-10-08

No results posted yet for this study

Summary

The histaminergic system is phylogenetically one of the oldest parts of the nervous system but it is a relatively recent discovery. It is involved with several vegetative functions like sleep, attention and learning, feeding and satiety, working memory, cognition, depression, and most of all arousal and energy

Conditions

Interventions

DRUG

Carbidopa

All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.

DIETARY_SUPPLEMENT

L-Histidine

Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of Miami

    lead OTHER

Principal Investigators

  • Kottil Rammohan, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-23
Primary Completion
2020-08-07
Completion
2020-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266965 on ClinicalTrials.gov